title: Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults.
abstract: OBJECTIVE
  To assess prognostic factors for adults with medulloblastoma in a multicenter, retrospective study.
  
  
  METHODS
  Data were collected by file review or mail inquiry for 253 adults treated between 1975 to 2004. Radiologists or surgeons assessed disease characteristics, such as volume and extension. Patients were classified as having either high- or standard-risk disease. Prognostic factors were analyzed.
  
  
  RESULTS
  Median patient age was 29 years. Median follow-up was 7 years. Radiotherapy was delivered in 246 patients and radiochemotherapy in 142. Seventy-four patients relapsed. Respective 5- and 10-year overall survival rates were 72% and 55%. Univariate analysis showed that survival significantly correlated with metastasis, postsurgical performance status, brainstem involvement, involvement of the floor of the fourth ventricle (V4), and radiation dose to the spine and to the posterior cerebral fossa (PCF). By multivariate analysis, brainstem, V4 involvement, and dose to the PCF were negative prognostic factors. In the standard-risk subgroup there was no overall survival difference between patients treated with axial doses of >or=34 Gy and patients treated with craniospinal doses <34 Gy plus chemotherapy.
  
  
  CONCLUSIONS
  We report the largest series of medulloblastoma in adults. Prognostic factors were similar to those observed in children. Results suggest that patients with standard-risk disease could be treated with radiochemotherapy, reducing doses to the craniospinal area, maintaining at least 50 Gy to the PCF. The role of chemotherapy for this group is still unclear. A randomized study should be performed to confirm these results, but because frequency is very low, such a study would be difficult.
authors.affiliation: Department of Radiation Oncology, Hôpital de la Timone, Marseille, France. laetitia.padovani@free.fr
authors.forename: Laetitia
authors.initials: L
authors.lastname: Padovani
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Sunyach
authors.forename: David
authors.initials: D
authors.lastname: Perol
authors.forename: Cedric
authors.initials: C
authors.lastname: Mercier
authors.forename: Claire
authors.initials: C
authors.lastname: Alapetite
authors.forename: Christine
authors.initials: C
authors.lastname: Haie-Meder
authors.forename: Sylvette
authors.initials: S
authors.lastname: Hoffstetter
authors.forename: Xavier
authors.initials: X
authors.lastname: Muracciole
authors.forename: Christine
authors.initials: C
authors.lastname: Kerr
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Wagner
authors.forename: Jean-Léon
authors.initials: JL
authors.lastname: Lagrange
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Maire
authors.forename: Didier
authors.initials: D
authors.lastname: Cowen
authors.forename: Didier
authors.initials: D
authors.lastname: Frappaz
authors.forename: Christian
authors.initials: C
authors.lastname: Carrie
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000704:Analysis of Variance; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate